These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 36353222)

  • 1. Development of combinatorial antibody therapies for diffuse large B cell lymphoma.
    Geanes ES; Krepel SA; McLennan R; Pierce S; Khanal S; Bradley T
    Front Med (Lausanne); 2022; 9():1034594. PubMed ID: 36353222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathologically complete remission to combination of invariant NK T cells and anti-CD20 antibody in a refractory HIV+ diffuse large B-cell lymphoma patient.
    Wang J; Zhang R; Ding X; Jin Y; Qin R; Xia B; Liao Q; Hu H; Song W; Wang Z; Zhang X; Xu J
    Immunotherapy; 2022 Jun; 14(8):599-607. PubMed ID: 35443802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PI3Kδ activation, IL6 over-expression, and CD37 loss cause resistance to the targeting of CD37-positive lymphomas with the antibody-drug conjugate naratuximab emtansine.
    Arribas AJ; Gaudio E; Napoli S; Yvon Herbaux CJ; Tarantelli C; Bordone RP; Cascione L; Munz N; Aresu L; Sgrignani J; Rinaldi A; Kwee I; Rossi D; Cavalli A; Zucca E; Stussi G; Stathis A; Sloss C; Davids MS; Bertoni F
    bioRxiv; 2023 Nov; ():. PubMed ID: 38014209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of PIM Kinases in DLBCL Targets MYC Transcriptional Program and Augments the Efficacy of Anti-CD20 Antibodies.
    Szydłowski M; Garbicz F; Jabłońska E; Górniak P; Komar D; Pyrzyńska B; Bojarczuk K; Prochorec-Sobieszek M; Szumera-Ciećkiewicz A; Rymkiewicz G; Cybulska M; Statkiewicz M; Gajewska M; Mikula M; Gołas A; Domagała J; Winiarska M; Graczyk-Jarzynka A; Białopiotrowicz E; Polak A; Barankiewicz J; Puła B; Pawlak M; Nowis D; Golab J; Tomirotti AM; Brzózka K; Pacheco-Blanco M; Kupcova K; Green MR; Havranek O; Chapuy B; Juszczyński P
    Cancer Res; 2021 Dec; 81(23):6029-6043. PubMed ID: 34625423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activity of tafasitamab in combination with rituximab in subtypes of aggressive lymphoma.
    Patra-Kneuer M; Chang G; Xu W; Augsberger C; Grau M; Zapukhlyak M; Ilieva K; Landgraf K; Mangelberger-Eberl D; Yousefi K; Berning P; Kurz KS; Ott G; Klener P; Khandanpour C; Horna P; Schanzer J; Steidl S; Endell J; Heitmüller C; Lenz G
    Front Immunol; 2023; 14():1220558. PubMed ID: 37600821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Binding to CD20 by anti-B1 antibody or F(ab')(2) is sufficient for induction of apoptosis in B-cell lines.
    Cardarelli PM; Quinn M; Buckman D; Fang Y; Colcher D; King DJ; Bebbington C; Yarranton G
    Cancer Immunol Immunother; 2002 Mar; 51(1):15-24. PubMed ID: 11845256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A bispecific antibody directly induces lymphoma cell death by simultaneously targeting CD20 and HLA-DR.
    Zeng J; Liu R; Wang J; Fang Y
    J Cancer Res Clin Oncol; 2015 Nov; 141(11):1899-907. PubMed ID: 25773122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antilymphoma effects of anti-HLA-DR and CD20 monoclonal antibodies (Lym-1 and Rituximab) on human lymphoma cells.
    Liu C; DeNardo G; Tobin E; DeNardo S
    Cancer Biother Radiopharm; 2004 Oct; 19(5):545-61. PubMed ID: 15650447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Depletion of the transcriptional coactivators CREB-binding protein or EP300 downregulates CD20 in diffuse large B-cell lymphoma cells and impairs the cytotoxic effects of anti-CD20 antibodies.
    Scialdone A; Khazaei S; Hasni MS; Lennartsson A; Gullberg U; Drott K
    Exp Hematol; 2019 Nov; 79():35-46.e1. PubMed ID: 31669559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
    Marcus R; Hagenbeek A
    Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody and immunotherapy in diffuse large B-cell lymphoma.
    Barraclough A; Hawkes EA
    Semin Hematol; 2023 Nov; 60(5):338-345. PubMed ID: 38072722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-CD38 Therapy with Daratumumab for Relapsed/Refractory CD20-Negative Diffuse Large B-Cell Lymphoma.
    Vockova P; Svaton M; Karolova J; Pokorna E; Vokurka M; Klener P
    Folia Biol (Praha); 2020; 66(1):17-23. PubMed ID: 32512655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, or Follicular Lymphoma.
    Falchi L; Ferrajoli A; Jacobs I; Nava-Parada P
    Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):508-518.e14. PubMed ID: 29934061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual-targeting immunotherapy of lymphoma: potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomas.
    Gupta P; Goldenberg DM; Rossi EA; Cardillo TM; Byrd JC; Muthusamy N; Furman RR; Chang CH
    Blood; 2012 Apr; 119(16):3767-78. PubMed ID: 22271448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cd20 Expression and Effects on Outcome of Relapsed/ Refractory Diffuse Large B Cell Lymphoma after Treatment with Rituximab.
    Rasheed AA; Samad A; Raheem A; Hirani SI; Shabbir- Moosajee M
    Asian Pac J Cancer Prev; 2018 Feb; 19(2):331-335. PubMed ID: 29479962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-CD20 treatment for B-cell malignancies: current status and future directions.
    Klein C; Jamois C; Nielsen T
    Expert Opin Biol Ther; 2021 Feb; 21(2):161-181. PubMed ID: 32933335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel anti-CD20 antibody TGLA with enhanced antibody-dependent cell-mediated cytotoxicity mediates potent anti-lymphoma activity.
    Lv M; Lin Z; Qiao C; Gen S; Lang X; Li Y; Feng J; Shen B
    Cancer Lett; 2010 Aug; 294(1):66-73. PubMed ID: 20202740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T cells armed with anti-CD3 x anti-CD20 bispecific antibody enhance killing of CD20+ malignant B cells and bypass complement-mediated rituximab resistance in vitro.
    Gall JM; Davol PA; Grabert RC; Deaver M; Lum LG
    Exp Hematol; 2005 Apr; 33(4):452-9. PubMed ID: 15781336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Performance of 89Zr-Labeled-Rituximab-PET as an Imaging Biomarker to Assess CD20 Targeting: A Pilot Study in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma.
    Jauw YW; Zijlstra JM; de Jong D; Vugts DJ; Zweegman S; Hoekstra OS; van Dongen GA; Huisman MC
    PLoS One; 2017; 12(1):e0169828. PubMed ID: 28060891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.